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Abstract
Introduction: Stress oxidative in chronic obstructive pulmonary disease (COPD)
impaired striated muscle thus worsening COPD clinical symptoms. Allopurinol as
antioxidant reduces stress oxidative in COPD so it can improve exercise capacity and
clinical symptoms of COPD patients. The aims of this study were to analyze the effect of
allopurinol on glutathione sulfhydryl (GSH) serum level, %FEV1, six-minute walking test
(6MWT), and COPD assessment test (CAT) score of COPD group C and D patients.
Methods: This was a pre and post test group clinical trials held in pulmonology
outpatient clinic in Dr. Moewardi general hospital, Surakarta from January to February
2018 using purposive sampling. The COPD group C and D patients were categorized as
intervention group which received allopurinol 300 mg/day for four weeks and a control
group which did not receive allopurinol. Glutathione sulfhydryl serum level, %FEV1,
6MWT, and CAT score were measured at baseline and after four weeks in both groups.
Results: A total of 37 stable COPD group C and D patients were included in this study.
The intervention group showed decreased of GSH level (52.58 ± 38.39) µg/ml and
CAT score (10.37 ± 4.46) which were statistically significant compared to control group
(p<0,05) while decreased of %FEV1 in intervention group (6.91 ± 10.60) and control
group (8.43 ± 11.26) were not significant statistically (p=0.94). The intervention group
also showed a significant increase of 6MWT (p=0.005) while the control group showed
no significant increase (p=0.109); however, the 6MWT differences in both groups were
not significant with p=0.057.
Conclusion:Allopurinol decreasedGSH serum level, did not influence%FEV1, increased
6MWT, and decreased CAT score of stable COPD group C and D patients.
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1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a pulmonary disease with increasing
prevalence due to increased harmful gas exposure and longer life expectancy. Male
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gender, smoker, and age over forty are more frequent to be affected by COPD. Cigarette
smoke or noxious agents is the primary cause of COPD [1-3].
Standard medical therapy for COPD which has been available so far is bronchodila-
tors as well as anti-inflammation drugs, and these have not covered the whole COPD
pathogenesis process so that it was not able to improve respiratory and skeletal muscle
functions as well as exercise capacity of COPD patients. Giving antioxidant as adjuvant
therapy is expected to be able to improve the effectiveness of stable COPD manage-
ment. The origin of cellular oxidant sources are from mitochondrial respiration, nicoti-
namide adenine dinucleotide phosphate hydrogen (NADPH) oxidase, dan xanthine oxi-
dase (XO), while the sources come from the environment are cigarette smoke, noxious
agents, and air pollution. An oxidant such as reactive oxygen species (ROS) mediates
inflammation process resulting in both damage and change of respiratory tract structure
so that respiratory tract obstruction and respiratory symptoms occur [2,4-7]. Xanthine
oxidase functions to change hypoxanthine into xanthine and later changes it to uric
acid. Xanthine oxidase enzyme oxidizes hypoxanthine with the support of oxygen and
releases ROS specifically superoxidant which then changed into hydrogen peroxide
(H2O2) causing endothelium dysfunction and muscle tissue injury. Glutathione sulfhydryl
(GSH) is an endogenous antioxidant which originates from liver and it is subsequently
distributed through blood then binds to ROS to form glutathione disulfide (GSSG). Muscle
injury due to ROS and hypoxemia secondary to chronic respiratory tract obstruction
promote skeletally and diaphragm muscle dysfunction as well as shortness of breath
[5, 8, 10].
Stable COPD patients classified into 4 groups which are A, B, C, and D. The quality
of life (QoL) of COPD patients primarily group C and D are mostly low or decreased due
to shortness of breath and daily activity dysfunction result from decline in breathing and
skeletal muscle’s capability while the QoL of group A and B are a little bit better. Chronic
obstructive pulmonary disease assessment test (CAT) is used to assess clinical symp-
toms while six minutes walking test (6MWT) is used to evaluate exercise capability of
stable COPD patients. Currently, the existing standardmedical therapy for COPD has not
fully achieved the aim of COPD management especially in reducing shortness of breath
and improving exercise capacity as well as ameliorating QoL of COPD patients [1, 2, 11].
Allopurinol, which until now has been known as anti hyperuricemia drug, can be used as
an additional medicine apart from standard therapy for stable COPD. Allopurinol which is
XO inhibitor is an antioxidant to prevent the formation of ROS which can be detected via
GSH serum level as well as to reduce muscle morphology damage specifically edema
in muscle fibers and mitochondria. Therefore giving this additional drug is expected to
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reduce skeletal muscle tissue damage and to boost exercise capacity of stable COPD
patients. The dose of allopurinol as an antioxidant is 300 mg per day as a single or split
dose [9, 12].
This study aimed to investigate the effects of allopurinol as oxidative stress regulator
on GSH serum level, percentage of forced expiratory volume in one second (%FEV1),
6MWT, and CAT score of stable COPD patients group C and D. All patients were still
given standard therapy for COPD according to guideline Global Initiative for Chronic
Obstructive Lung Disease (GOLD) 2017.
2. Methods
This was a pre and post test quasi-experimental study which was conducted in pul-
monology outpatient clinic of Dr. Moewardi hospital, Surakarta from January to February
2018 by using purposive sampling. This study involved 38 stable COPD patients group
C and D who were willing to join this study by signing the informed consents. Patients
with acute exacerbation, intra and extrapulmonary infection, acute and chronic kidney
disorder, diabetes mellitus, cardiac disease, neuromusculoskeletal abnormality, intra
and extrapulmonary malignancy, active smoker, uric acid level of < 4 mg/dl, previously
had allopurinol consumption, antioxidant consumption such as vitamin C and E, diuretic,
cyclophosphamide, probenecid, anticoagulant at least a week prior to the start of this
study, and post thorax or abdominal surgery were excluded from this study.
The study subjects were grouped into intervention (n=19) and control (n=19) groups at
the beginning of the study, however, one subject in the control group experienced traffic
accident and could not continue this study so at the end of the study there were only 37
subjects. Allopurinol 300mg/day single dose was given to the intervention group for 4
weeks (28 days) while the control group received nothing but their standard therapy for
COPD.
The data comprised of categorical and numerical data. Chi-square or Fisher exact
test was used to analyzing categorical data. Numerical data was presented in mean
with standard deviation. All data were statistically assessed with SPSS version 17 and
p-value of < 0.05 was considered significant.
Adverse events of allopurinol were monitored by phone calls and direct examinations
during their routine follow-ups at the outpatient clinic. None of the subjects reported any
adverse event during this study period. This study had been approved by research ethics
committee of Dr. Moewardi hospital/Faculty of Medicine of Universitas Sebelas Maret,
Surakarta.
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3. Results
Baseline characteristics of the subjects were age, gender, education, occupation, body
weight, body height, body mass index (BMI), smoking status, yearly exacerbations, and
COPD groups. Subjects characteristics’ data and study variables of both groups were
statistically homogenous with a p-value > 0.005 as could be seen in Table 1.
3.1. Glutathione Sul ydryl (GSH) serum level
Before the intervention, the GSH level of the intervention group was 97.80±25.64 µg/ml
while the control group was 99.19±32.23 µg/ml. By the end of the study, the GSH level
of intervention group decreased significantly into 45.22±23.52 µg/ml (p=0.000). Mean-
while, the control group which received standard therapy alone experienced a slight
decrease (89.85± 35.84 µg/ml; p=0,291). The difference of GSH level (post-pre) between
the two groups was statistically significant (p=0.001). The GSH serum level results were
shown in Table 2.
3.2. Percentage of forced expiratory volume in 1 second (%FEV1)
The value of %FEV1 at baseline in both intervention and control groupswere 40.34±17.40
and 38.66±15.41 respectively. After four weeks the value decreased significantly, they
became 33.42±16.89 and 30.23±11.67 in intervention and control groups respectively.
However, when both groups were compared statistically, no significant difference was
found (p=0.940). Table 3 showed the value of %FEV1 in this study.
3.3. Six-minute walking test (6MWT)
The 6MWT results of both groups intervention and control at baseline were
255.05±67.23 m and 227.72±38.42 m, respectively. By the end of the study period,
the intervention group had a significant improvement in 6 MWT (265.00±62.08 m;
p=0.005). There was also an improvement in the control group. However, it was not
statistically significant (233.33±38.56 m; p=0.109). Statistically, there was no difference
in 6MWT between the two groups (p=0.057). The 6MWT results were showed in Table
4.
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Table 1: Baseline Characteristics of the Subjects.
Variables Groups
Intervention (n = 19) Control (n = 18) p-value
Gender3
Male 16(84.2%) 15(83.3%) 0.942
Female 3(15.8%) 3(16.7%)
Age1 65.32±5.99 65.83±7.51 0.968
Educations3
No education 1(5.3%) 0(0.0%) 0.479
Elementary 10(52.6%) 7(38.9%)
Junior high school 3(15.8%) 3(16.7%)
Senior high school/STM 5(26.3%) 5(27.8%)
Diploma 2 0(0.0%) 2(11.1%)
Diploma 3 0(0.0%) 1(5.6%)
Occupations3
Army/Police 2(10.5%) 1(5.6%)
Government officer 2(10.5%) 2(11.1%)
Teacher 0(0.0%) 1(5.6%)
Private officer 6(31.6%) 2(11.1%)





Village officer 1(5.3%) 0(0.0%)
Becak driver 1(5.3%) 0(0.0%)
Weight1 52.16±11.35 53.39±11.34 0.065
Height1 159.42±6.35 161.56±4.69 0.32
BMI1 20.60±4.81 20.53±4.59 0.132
Uric acid level1 5.48±1.11 5.21±1.41 0.642
Smoking Status3
Smoker
Mild Brinkman Index (BI) 1(5.3%) 0(0.0%) 0.537
Moderate BI 9(47.4%) 6(33.3%)
Severe BI 6(31.6%) 9(50%)
Non-smoker 3(15.8%) 3(16.7%)
COPD Groups3
C 3(15.8%) 5(27.8%) 0.314
D 16(84.2%) 13(72.2%)
Yearly exacerbations2 1.58±0.69 1.50±0.79 0.62
Notes: 1independent sample T-test, 2Mann Whitney, and 3Chi square
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Table 2: Glutathione Sulfhydryl (GSH) Serum Level Pre, Post, and The Difference Between Intervention and
Control Groups.
Groups Glutathione Sulfhydryl Serum Level
Pre Post p Δ (Post-Pre)
Intervention 97.80 ± 25.64 45.22 ± 23.52 0.0001 -52.58 ± 38.39
Control 99.19 ± 32.23 89.85 ± 35.84 0.2911 -9.34 ± 36.35
p 0.5582 0.0002 0.0012
Notes: 1paired sample t-test, 2Mann Whitney.
Table 3: Percentage of Forced Expiratory Volume in 1 second (%FEV1) Pre, Post, and The Difference Between
Intervention and Control Groups.
Groups Percentage of Forced Expiratory Volume in 1 second
Pre Post p Δ (Post-Pre)
Intervention 40.34 ± 17.40 33.42 ± 16.89 0.0111 6.91 ± 10.60
Control 38.66 ± 15.41 30.23 ± 11.67 0.0061 8.43 ± 11.26
p 0.7592 0.7753 0.9403
Notes: 1paired sample t-test,2independent sample t-test, 3 Mann Whitney.
Table 4: Six-minute walking test (6MWT) Pre, Post, and The Difference Between Intervention and Control
Groups.
Groups Six-minute walking test
Pre Post p Δ (Post-Pre)
Intervention 255.05 ± 67.23 265.00 ± 62.08 0.0051 9.95 ± 13.73
Control 227.72±38.42 233.33±38.56 0.1091 5.61 ± 14.08
p 0.1412 0.0732 0.0573
Notes: 1paired sample t-test,2independent sample t-test, 3Mann Whitney.
3.4. COPD assessment test (CAT) score
The mean CAT score of intervention and control groups at entry point were 22.57±7.60
and 18.67±7.38, respectively. In the intervention group, the score decreased significantly
after the administration of allopurinol (12.16±4.63; p=0.000). There was no significant
decrease in CAT score in the control group at the end of the study period (17.50±7.70;
p=0.085). A statistically significant difference was observed in both groups (p=0.000).
Table 5 showed the results of CAT score in this study.
4. Discussion
Allopurinol had been proved to play a role as antioxidative stress which is assessed
by the changing of GSH serum level while its role as anti-inflammation could not be
proved in this study as the value of %FEV1 remained decreased. Males were affected
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Table 5: COPD assessment test (CAT) Score Pre, Post, and The Difference Between Intervention and Control
Groups.
Groups COPD assessment test Score
Pre Post p Δ (Post-Pre)
Intervention 22.53 ± 7.60 12.16 ± 4.63 0.0001 -10.37 ± 4.46
Control 18.67 ± 7.38 17.50 ± 7.70 0.0851 -1.17 ± 2.71
p 0.1182 0.0143 0.0002
Notes: 1paired sample t, 2Mann Whitney, 3independent sample t-test.
by COPD more than females were in this study. Education and occupation may also
influenceCOPDoccurrence. Low education is related to poor knowledge on the dangers
of smoking habit, cigarette smoke, and exposure to noxious agents which affect health,
particularly in the lungs. The majority of study subjects in the intervention group were
employees while in the control group were labors. Global initiative for COPD declares
that low socioeconomy is one of the COPD risk factors, presumably, it is related to in
an outdoor pollutant exposure, the crowd, poor nutrition, infection and other socioe-
conomic related factors [1, 3, 14]. Eighty percent of our study subjects were smokers.
Cigarette smoke exposure was classified based on BI, and most of the subjects were
categorized as moderate. High smoking habit is one of the factors affecting high COPD
incidence [3]. Despite the baseline characteristics differences between the two groups,
the two groups were homogenous statistically so the variables could be compared one
another.
Glutathione sulfhydryl originates in liver and functions as endogenous antioxidant
found in sulfhydryl cysteine binding. Organs which mainly use GSH production in the
liver as an antioxidant are lungs, kidney, and gut [15]. Our findings revealed that the GSH
level in the allopurinol group decreased significantly. Allopurinol 300mg given daily as a
single dose for four weeks lowered GSH level. This was due to oxidative stress regulator
effect owned by allopurinol. This finding was similar to Ichinose et al. and Heunks et al.
findings. Ichinose et al. reported that allopurinol 300mg daily as XO inhibitor given for
four weeks suppressed the production of peroxynitrite and RNS, while Heunks et al.
found that allopurinol 300mg daily administered for two days lowered the formation of
GSSG and MDA [9, 10, 12].
COPD patients experience decreased FEV1 progressively every year by 50 to 60 ml
[16, 17]. As in our study the %FEV1 value decreased in both groups. Ichinose et al. also
reported that there was no change in respiratory tract volume of subjects given allop-
urinol 300mg/day [12]. This phenomenon was due to persistent inflammation process
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in the respiratory tract and lung parenchyma leading to progressive respiratory tract
obstruction and finally caused airway remodeling in COPD patients.
COPD patients experience decreased exercise capacity because of reduced muscle
mass, shortness of breath, and airway obstruction. The 6MWT is the most common
method used in lung rehabilitation program since it is cheap, easy to use, and practical.
It is also a reliable indicator. Thus we used it in this study. The minimal significant dif-
ference (MID) in 6MWT according to European Respiratory Society (ERS) dan American
Thoracic Society (ATS) guideline is 30 m [18, 19]. The administration of allopurinol as
antioxidant could reduce muscle damage which was expected to lessen skeletal muscle
tissue damage, including diaphragmmuscle of COPD patients. Our findings showed that
COPD patients given allopurinol had significant improvement in their exercise capacity
clinical symptoms of stable COPD patients was important to be evaluated. This finding
could not be compared to other studies since it was the first study that ever investigated
about it. Factors that could influence the 6MWT finding in this study were allopurinol
effect as XO inhibitor, predominantly male gender in this study who had high motivation
in doing 6MWT, and most of the subjects had ever done 6MWT before [20].
Worsened clinical symptoms can detain the daily activity of COPD patients resulting in
a decrease of QoL. CAT is used to measure the QoL of COPD patients. This study used
score showing improved clinical symptoms was a decrease of 2-3 points [1, 21, 22]. In
our findings allopurinol affected on decreasing the CAT score of stable COPD patients
group C and D. However this study could not be compared to others as this was the
first study whichever investigated the effect of allopurinol on clinical symptoms of stable
COPD group C and D. Allopurinol 300 mg daily inhibited XO enzyme and prevented
the formation of free radicals so that oxidative stress process could be prevented sys-
tematically, thus skeletal injury was impeded resulting in improved respiratory muscle
contractility and skeletal muscle. Therefore shortness of breath and peripheral skeletal
muscle dysfunction ameliorated which eventually improved clinical symptoms as well
as exercise capacity [9, 10, 12]. As a limitation, this study was only able to prove the
hypothesis of allopurinol effects as an antioxidant on GSH serum level, 6MWT, and CAT
score of stable COPD group C and D while effect as anti-inflammation had not been
proved. Therefore a further study was needed to prove the anti-inflammatory effect of
allopurinol.
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5. Conclusions
Allopurinol 300 mg daily given for 4 weeks significantly lowered GSH serum level,
improved 6MWT, and reduced CAT score but did not affect the %FEV1 value of patients
with stable COPD group C and D.
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